| Literature DB >> 32705344 |
Bernd Martin Jänigen1, Johann Hempel2, Philipp Holzner2, Johanna Schneider3, Stefan Fichtner-Feigl2, Oliver Thomusch2, Hannes Neeff2, Przemyslaw Pisarski2, Torben Glatz2,4.
Abstract
BACKGROUND: In end-stage renal transplant recipients with autosomal-dominant polycystic kidney disease (ADPKD), the imperative, optimal timing, and technique of native nephrectomy remains under discussion. The Freiburg Transplant Center routinely performs a simultaneous ipsilateral nephrectomy.Entities:
Keywords: ADPKD; Polycystic kidney disease; Renal transplantation; Simultaneous unilateral nephrectomy
Mesh:
Year: 2020 PMID: 32705344 PMCID: PMC7471159 DOI: 10.1007/s00423-020-01939-3
Source DB: PubMed Journal: Langenbecks Arch Surg ISSN: 1435-2443 Impact factor: 3.445
Fig. 1Study profile. The study compares 193 consecutive ADPKD renal transplant recipients receiving simultaneous ipsilateral nephrectomy with a propensity score-based matched pair control group
Preoperative baseline characteristics of study population
| ADPKD group | Matched control group | |||
|---|---|---|---|---|
| *Donor age (years) | 53.0 (95% CI 51.0–56.0) | 57.0 (95% CI 54.0–60.0) | 0.1744 | |
| Donor gender (female/male) | 98 (50.8%)/95 (49.2%) | 86 (44.6%)/107 (55.4%) | 0.2623 | |
| Donor BMI (kg/m2) | 25.6 (95% CI 24.8–26.1) | 25.3 (95% CI 24.7–25.9) | 0.3551 | |
| *Recipient age (years) | 54.6 (95% CI 53.0–56.2) | 55.7 (95% CI 53.0–59.1) | 0.7703 | |
| Recipient gender (female/male) | 88 (45.6%)/105 (54.4%) | 61 (31.6%)/132 (68.4%) | 0.0065 | |
| Recipient BMI (kg/m2) | 25.1 (95% CI 24.6–26.2) | 25.2 (95% CI 24.7–25.9) | 0.9309 | |
| ASA status recipient (in %) | 1 2 3 4 | 0 (0.0%) 63 (32.6%) 122 (63.2%) 8 (4.2%) | 1 (0.5%) 54 (28.0%) 130 (67.4%) 8 (4.2%) | 1.0000 0.3757 0.4543 1.0000 |
| *Time on dialysis (in d) | 964 (95% CI 577.0–1345.4) | 909 (95% CI 719.4–1229.7) | 0.8064 | |
| *Type of transplantation (in %) | Cadaveric ABOc (living) ABOi (living) | 96 (49.7%) 75 (38.9%) 22 (11.4%) | 94 (48.7%) 76 (39.4%) 23 (11.9%) | 0.9189 1.0000 1.0000 |
| *Cold ischemic time (in min.) | 328.0 (95% CI 216.0–436.6) | 278.0 (95% CI 181.4–435.4) | 0.1088 | |
| *Year of transplantation | 2008 (95% CI 2007–2009) | 2008 (95% 2007–2009) | 0.2102 | |
| *No. of transplantation (in %) | 1st 2nd 3rd | 187 (96.9%) 6 (3.1%) 0 (0.0%) | 184 (95.3%) 7 (3.6%) 2 (1.0%) | 0.5999 1.0000 0.4987 |
| *Panel reactive antibodies (in %) | 0.0 (95% CI 0.0–0.0) | 0.0 (95% CI 0.0–0.0) | 0.6927 | |
| *HLA-Mismatches (no. of mismatches) | 3.0 (95% CI 3.0–4.0) | 3.0 (95% CI 3.0–3.0) | 0.2351 | |
Data are n (%) or median ± 95% CI. p values are estimated with Mann-Whitney U test for calculated data, and 2-tailed Fisher’s exact test for categorical data
*propensity score-based match criteria
Intra- and postoperative course and medical complications
| ADPKD group | Matched control group | ||
|---|---|---|---|
| CNI/MPA/steroids (in %) | 191 (99.0%) | 189 (97.9%) | 0.6850 |
| IL2-RA (in %) | 114 (59.1%) | 104 (53.9%) | 0.3555 |
| ATG (in %) | 12 (6.2%) | 11 (5.7%) | 1.0000 |
| Rituximab/immunoadsorption (in %) | 22 (11.4%) | 23 (11.9%) | 1.0000 |
| Operative time (in min.) | 169.0 (95% CI 159.8–175.6) | 139.0 (95% CI 131.4–145.0) | < 0.0001 |
| Anastomosis time (in min.) | 26.0 (95% CI 25.0–29.0) | 29.0 (95% CI 27.0–30.0) | 0.0186 |
| Weight of polycystic kidney (in g) | 1879.8 ± 162.9 | ||
| Malignant specimen (in %) | 2 (1.0%) | ||
| Delayed graft function (in %) | 5 (2.6%) | 4 (2.1%) | 1.0000 |
| Hospital stay (in d) | 19.0 (95% CI 18.0–20.0) | 18.0 (95% CI 17.0–19.0) | 0.1292 |
| Intensive care unit stay (in d) | 0.0 (95% CI 0.0–0.0) | 0.0 (95% CI 0.0–0.0) | 0.9512 |
| Renal biopsies within 30 days (in %) | 50 (25.9%) | 45 (23.3%) | 0.6366 |
| Biopsy proven acute rejections ≤ 30days (in %) | 16 (8.3%) | 23 (11.9%) | 0.3109 |
| Inpatient CMV infections > 1000 copies (in %) | 5 (2.6%) | 12 (6.2%) | 0.1346 |
| Inpatient UTI (in %) | 78 (40.4%) | 56 (29.0%) | 0.0246 |
| Postoperative pneumonia (in %) | 5 (2.6%) | 9 (4.7%) | 0.4152 |
Data are n (%) or median ± 95% CI. p values are estimated with Mann-Whitney U test for calculated data, and 2-tailed Fisher’s exact test for categorical data. Weight of polycystic kidney is expressed in mean ± SD
Surgical morbidity and mortality within first year after KTx
| ADPKD group | Matched control group | |||
|---|---|---|---|---|
| Venous thrombosis (in %) | 2 (1.0%) | 0 (0.0%) | 0.4987 | |
| Severe arterial stenosis (in %) | 2 (1.0%) | 3 (1.6%) | 1.0000 | |
| Graft nephrectomy ≤ 30days (in %) | 2 (50.0%) | 2 (66.7%) | 1.0000 | |
| Intraoperative RBCT (in %) | 44 (22.8%) | 13 (6.7%) | 0.0001 | |
| Postoperative bleeding/hematoma | 16 (8.3%) | 18 (9.3%) | 0.8578 | |
| Postoperative RBCT (> 1 RBCT) post-OP day < 3 days | 88 (45.6%) | 43 (22.3%) | 0.0001 | |
| Postoperative RBCT (> 1 RBCT) post-OP day 3–7 days | 59 (30.6%) | 48 (24.9%) | 0.2554 | |
| Urinary obstruction (in %) | 8 (4.2%) | 11 (5.7%) | 0.6391 | |
| Urinary leakage (in %) | 5 (2.6%) | 3 (1.6%) | 0.7237 | |
| Lymphoceles (in %) | 20 (10.4%) | 26 (13.5%) | 0.4324 | |
| Wound infection (in %) | 7 (3.6%) | 13 (6.7%) | 0.2504 | |
| Dehiscent fascia (in %) | 2 (1.0%) | 5 (2.6%) | 0.4488 | |
| Hernia (in %) | 2 (1.0%) | 3 (1.6%) | 1.0000 | |
| Other surgical complications with reoperation ≤ 30 days (in %) | 1 (0.5%) | 1 (0.5%) | 1.0000 | |
| Reoperation | ≤ 30 days (in %) Within first year (in %) | 24 (12.4%) 48 (24.9%) | 33 (17.1%) 55 (28.5%) | 0.2509 0.4900 |
| Mortality ≤ 30 days (in %) | 1 (0.5%) | 0 (0.0%) | 1.0000 | |
Data are n (%). p values are estimated with 2-tailed Fisher’s exact test for categorical data
Clavien-Dindo classification
| ADPKD-group | Matched control group | ||
|---|---|---|---|
| I | 22 (11.4%) | 39 (20.2%) | 0.0250 |
| II | 132 (68.4%) | 109 (56.5%) | 0.0206 |
| IIIa | 3 (1.6%) | 4 (2.1%) | 1.0000 |
| IIIb | 27 (13.4%) | 36 (18.7%) | 0.2705 |
| IVa | 8 (4.2%) | 5 (2.6%) | 0.5744 |
| IVb | 0 (0.0%) | 0 (0.0%) | 1.0000 |
| V | 1 (0.5%) | 0 (0.0%) | 1.0000 |
Data are n (%). p values are estimated 2-tailed Fisher’s exact test for categorical data
Fig. 2Kaplan-Maier survival probability of ADPKD group (blue) and control group (green). (a) Patient survival (p = 0.6537); (b) death-censored graft survival (p = 0.5479)
Fig. 3Correlation of red blood cell transfusions and weight of removed polycystic kidney
LOESS smoothing span 80%
Indication for nephrectomy prior and after KTx
| Prior KTx (group a) | Post KTx (group c) | ||
|---|---|---|---|
| Cyst infection/UTI (in %) | 3 (7.9%) | 16 (34.8%) | 0.0038 |
| Bleeding/hematuria (in %) | 3 (7.9%) | 3 (6.9%) | 1.0000 |
| Pain (in %) | 5 (13.2%) | 6 (13.1%) | 1.0000 |
| Renal mass/digestive problems (in %) | 27 (71.1%) | 17 (37.0%) | 0.0023 |
| Renal cell carcinoma in ipsilateral kidney (in %) | 0 (0.0%) | 2 (4.4%) | 0.4986 |
| Suspicion for renal cell carcinoma (in %) | 0 (0.0%) | 1 (2.2%) | 1.0000 |
| Other (in %) | 0 (0.0%) | 1 (2.2%) | 1.0000 |
Data are n (%). p values are estimated 2-tailed Fisher’s exact test for categorical data